7/26/2021 7:08:58 AM
Iterum Therapeutics Says FDA Issues Complete Response Letter For Oral Sulopenem
2/3/2021 11:44:12 PM
Iterum Therapeutics Increases Size Of Offering And Purchase On A Firm Commitment Basis 34.8 Shares At $1.15/Shr
2/1/2021 7:12:26 AM
Iterum Announces Collaboration With EVERSANA To Support Oral Sulopenem Launch
1/25/2021 7:14:23 AM
Iterum Says FDA Accepted For Review NDA For Sulopenem Etzadroxil/probenecid
12/23/2020 7:09:55 AM
Iterum Therapeutics' Michael Dunne Resigns As Chief Scientific Officer
12/7/2020 8:20:28 AM
Iterum Announces Filing Of A U.S. National Phase Patent Application